Who
Dan Zabrowski
Director
Company insider
Files Form 4 as: Director, Actuate Therapeutics; Director, Apexigen.
In numbers
- Trades disclosed
- 6
- Buys
- 0
- Sells
- 0
- Bought
- $0
- Sold
- $0
- Companies
- 2
- Companies where not an officer
- 2
- First trade
- 29 Sep 2022
- Last trade
- 21 May 2026
- Last filed
- 22 May 2026
Companies traded
Activity over time
Not enough dated trades to draw.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 21 May 2026filed 22 May 2026 | ACTU Actuate Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —15,000 at $0.00 | filing |
| 21 May 2026filed 22 May 2026 | ACTU Actuate Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —15,000 at $0.00 | filing |
| 22 May 2025filed 23 May 2025 | ACTU Actuate Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —15,000 at $0.00 | filing |
| 12 Aug 2024filed 14 Aug 2024 | ACTU Actuate Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —15,000 at $0.00 | filing |
| 23 Aug 2023filed 25 Aug 2023 | Apexigenoption or derivative | SEC FORM 4 Code D | —100,000 | filing |
| 29 Sep 2022filed 3 Oct 2022 | Apexigenoption or derivative | SEC FORM 4 Code A | —100,000 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.
Sectors
No trade we could place in a sector.